Gene Therapy Breakthrough: Single Treatment Reverses Symptoms In Mouse Model Of Rare Brain Disorder

SEATTLE — Researchers have achieved the first demonstration in mice of using gene therapy to reverse hallmark symptoms of SYNGAP1-related disorder, a devastating condition affecting an estimated 1 million people worldwide. The treatment reduced abnormal brain electrical activity and corrected the brain wave patterns that are linked to many of the disorder’s problems, suggesting potential for a single intervention to reduce reliance on the multiple medications patients currently need.

The study, published in Molecular Therapy, demonstrates that delivering a functional copy of the SYNGAP1 gene via a modified virus can restore key measures of brain function in mice, even when administered during stages equivalent to early childhood in humans. Unlike conventional treatments that merely manage symptoms, this approach targets the genetic root cause of the disorder.

“This is the first successful demonstration of SYNGAP1 gene supplementation for SYNGAP1-related disorders with a multifaceted rescue of both epileptiform and behavioral phenotypes,” the research team from the Allen Institute for Brain Science and BioMarin Pharmaceutical reported.

Children with SYNGAP1-related disorders face intellectual disability, severe epilepsy, motor impairments, and behavioral problems such as hyperactivity and impulsivity. The SYNGAP1 gene provides instructions for making a protein critical for proper brain synapse function (the connection points where neurons communicate). When one copy of the gene is missing or impaired, the brain develops abnormally. Current treatment involves multiple medications to control seizures and manage behaviors, but these therapies don’t fix the underlying problem and often come with substantial side effects.

Breaking Through Technical Barriers

The researchers, led by Boaz Levi, faced a significant hurdle: the SYNGAP1 gene is too large to fit inside the standard delivery vehicle used for gene therapy. Adeno-associated viruses (AAV) typically can’t package genetic material larger than 4.7 kilobases, but the full SYNGAP1 gene measures about 5.1 kilobases.

Despite exceeding size limits, the scientists successfully engineered a viral vector that could deliver the complete, functional gene to neurons throughout the brain. Analysis showed that about three-quarters of packaged genomes were full-length. The team chose to deliver the SYNGAP1-Aα1 isoform, one of several versions of the protein that plays a particularly important role in behavioral and brain activity.

Brain Waves Return to Normal Patterns In SYNGAP-1 Mice

When the researchers tested their gene therapy in mice modeling SYNGAP1-related disorder, they observed substantial improvements across multiple measures of brain function. Perhaps most striking were changes in brain wave patterns, which are profoundly disrupted in both mouse models and human patients with the condition.

The brain produces electrical oscillations at different frequencies, each associated with specific cognitive functions. Slow delta waves dominate during deep sleep, theta waves appear during memory formation, alpha waves emerge during wakeful rest, beta waves accompany active thinking, and gamma waves facilitate information processing across brain regions.

In untreated mice with SYNGAP1 deficiency, the researchers observed elevated slow-wave and theta activity along with reduced alpha, beta, and gamma oscillations. These disrupted patterns have been linked to problems with learning, memory, attention, and sensory processing (the same cognitive struggles seen in patients).

After gene therapy treatment, particularly at mid- and high doses, brain wave patterns normalized across all frequency bands. The treatment reduced excessive slow-wave and theta activity while restoring alpha, beta, and gamma oscillations to healthy levels. These changes indicate restoration of more typical brain activity patterns across brain regions.

The gene therapy also reversed behavioral abnormalities characteristic of the disorder. Untreated mice showed hyperactivity, traveling nearly twice the distance of healthy mice in open field tests. They also displayed reduced fear of heights and increased risk-taking behavior, repeatedly poking their noses over the edge of elevated platforms (behaviors that parallel the impulsivity and fearlessness seen in human patients).

Treatment administered at postnatal day 21, roughly equivalent to early childhood in humans, reduced hyperactivity in a dose-dependent manner. At the highest doses, treated mice traveled distances comparable to healthy animals. The therapy also normalized risk-taking behaviors, with mice showing more typical caution on elevated platforms. These behavioral improvements emerged even when treatment was delayed until after the early postnatal period, challenging the notion that intervention must occur extremely early to be effective.

Reducing Abnormal Brain Electrical Activity

One of the most dangerous aspects of SYNGAP1-related disorders is abnormal electrical activity in the brain. The mice experienced frequent interictal spikes (abnormal electrical discharges between seizures), averaging 112 spikes per hour in the parietal region. After gene therapy, this number dropped to just 8 spikes per hour at effective doses, representing about a 93 percent reduction.

These interictal spikes are known to disrupt normal brain activity and have been linked to cognitive impairment in epilepsy patients, making their reduction particularly meaningful. However, the treatment did not completely prevent spontaneous generalized tonic-clonic seizures in all animals. Some mice in each treatment group still experienced seizures, though the study had too few animals to determine whether treatment changed seizure frequency.

The research team tested two different administration approaches: delivery to newborn mice at postnatal day 2 and to juvenile mice at day 21. Neonatal treatment showed only partial effectiveness, increasing SynGAP protein levels from 0.55 to 0.69 (normalized to healthy mice at 1.0) but failing to significantly improve behavioral symptoms.

Juvenile treatment proved more successful, particularly at higher doses that fully restored SynGAP protein levels to wild-type. This timing corresponds to the typical age of diagnosis in human patients, approximately 1 to 3 years old, making the findings especially relevant for clinical translation. The improved outcomes with juvenile treatment likely stem from brain-wide distribution of the therapeutic gene achieved through intravenous delivery and protein levels reaching normal amounts.

Moving Toward Human Trials

The doses used in the effective juvenile treatments fall within ranges used in approved human gene therapies. Zolgensma, an FDA-approved AAV gene therapy for spinal muscular atrophy, uses comparable dose levels, suggesting the SYNGAP1 approach could be similarly feasible in patients.

Several questions remain before human trials can begin. The long-term safety of the treatment needs evaluation, including monitoring for any adverse effects from viral delivery or potential protein overexpression. The researchers noted that protein levels appeared to plateau even with increasing doses of the therapeutic gene, suggesting a natural ceiling effect that may prevent excessive expression.

Optimizing which specific neurons should receive the gene could further improve outcomes. The current study used a promoter that drives expression broadly across all neurons, but targeting specific cell types (particularly excitatory neurons, where SYNGAP1 is naturally most abundant) might enhance effectiveness while minimizing off-target effects.

The achievement marks a turning point for families affected by SYNGAP1-related disorders. For years, treatment has meant managing an ever-growing list of symptoms with multiple medications, each bringing its own side effects and limitations. Gene therapy offers the possibility of addressing the root cause with a single treatment, potentially transforming the trajectory of children’s lives shortly after diagnosis rather than managing decline over decades.